- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04801030
COVID-19 Vaccine Hesitancy Among African Americans
Using Multi-strategies to Address COVID-19 Vaccine Hesitancy Among African Americans
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The goal of this application is to develop and test the feasibility and impact of a multi-layered, culturally-appropriate social marketing intervention targeting COVID-19 VH African Americans to increase uptake and completion of vaccine series in Nashville/Davidson County, Tennessee (TN). Investigators will partner with members of National Association for the Advancement of Colored People, Nashville Health Disparities Coalition, and Congregational Health Education Network to serve as an advisory committee. Investigators will also partner with Meharry Medical College (MMC) clinics and Tennessee Department of Health's (TDH) Immunization Program.
Aim 1. Engage with key stakeholders to develop a multi-layered, culturally-appropriate social marketing intervention targeting African Americans who are COVID-19 VH. Investigators will adapt an existing message library using the Health Belief Model,Theory of Reasoned Action, previous VH research, preliminary data of investigators, and feedback from community partners. Next, investigators will conduct semi-structured interviews with 25-30 VH individuals and 5-10 COVID-19 experts to elicit feedback on draft content. Qualitative data will be collected and analyzed iteratively, informing successive intervention modifications to cover a range of concerns for VH individuals, enhance message relevance, and determine media outlets for dissemination. Next, investigators will pre-test intervention prototypes with 16 COVID-19 VH individuals to make final modifications.
Aim 2a. Conduct a pilot study of the intervention and study protocol to demonstrate feasibility and assess impact. Investigators will conduct a pilot study using an experimental field trial design in three TN counties: Davidson County (1 intervention site) and Shelby and Hamilton Counties (2 control sites). COVID-19 vaccine uptake, primary outcome, assessed using: 1) aggregate data from partner clinics and TN immunization registry (TennIIS) and 2) individual, pre-post data from a marketing firm using random digit dialing (RDD). H1: COVID-19 vaccination rates will be higher for VH African Americans at intervention site compared to control sites. Implementation outcomes are feasibility, fidelity, acceptability, appropriateness, and penetration.
Aim 2b. To retrospectively explore knowledge, attitudes, intentions, and implementation outcomes post-intervention. Investigators will use qualitative methods to identify perceived acceptance of different types of media and webpage along with perceived change in knowledge, attitudes, and intentions from African Americans by degree of VH. Investigators will also explore appropriateness, feasibility, penetration, and fidelity as it relates to the social marketing intervention from 3 providers, 3 community-based organization (CBO) staff, and 2 TDH staff. Participants will be identified using RDD and community partner networks.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37208
- Meharry Medical College
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- African American
- Unvaccinated for COVID-19
- Vaccine hesitant
- 18 years and older
- Speaks English
Exclusion Criteria:
- Not African American
- Receipt of COVID-19 vaccination
- under 18 years of age
- Does not speak English
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Culturally-appropriate social marketing campaign
Participants will receive a multi-layered, social marketing campaign which is deemed culturally appropriate.
This will occur over a 6 month -time period.
Rates will be observed at 0, 6, and 12 months.
|
The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks.
Participants receive culturally-tailored message on COVID-19 and the vaccine.
The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone.
On the website, participants will be prompted to select their top concerns from a list.
Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
|
|
Kein Eingriff: Control Arm 1
Participants will receive no intervention, only to serve as a control site.
Rates will be observed at 0, 6, and 12 months.
|
|
|
Kein Eingriff: Control Arm 2
Participants will receive no intervention, only to serve as a control site.
Rates will be observed at 0, 6, and 12 months.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recruitment rates
Zeitfenster: 6 months
|
percent enrolled in study
|
6 months
|
|
Retention rates
Zeitfenster: 1 year
|
percent completed baseline survey, percent completed follow-up survey
|
1 year
|
|
data collection processes
Zeitfenster: 1 year
|
percent ascertained COVID 19 vaccine status post-intervention
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
COVID-19 vaccine rates
Zeitfenster: 6 months
|
Number of individuals vaccinated post-intervention
|
6 months
|
|
Attitudes toward COVID-19 vaccine
Zeitfenster: 6 months
|
Change in attitudes toward COVID-19 vaccine
|
6 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Jennifer C Erves, PhD, Meharry Medical College
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 21-03-1076
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Covid19
-
Anavasi DiagnosticsNoch keine Rekrutierung
-
Ain Shams UniversityRekrutierung
-
Israel Institute for Biological Research (IIBR)Abgeschlossen
-
Hospital do CoracaoAbgeschlossen
-
Colgate PalmoliveAbgeschlossenCovid19Vereinigte Staaten
-
Christian von BuchwaldAbgeschlossen
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdAktiv, nicht rekrutierend
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitatsspital ZurichAnmeldung auf Einladung
-
Alexandria UniversityAbgeschlossen
-
Henry Ford Health SystemAbgeschlossen